Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

5,456,763 hits in 0.776 seconds
Refine your search
Collection
Years
Select All   Deselect All   Toggle Selection   Add To Mindlist   Mail Export   File Export
1.
PAPER CURRENT
Advances in Fungal Phylogenomics and Its Impact on Fungal Systematics (2017)
Elsevier
Publication Date: 2017-10-22
Description: Publication date: Available online 20 October 2017 Source: Advances in Genetics Author(s): Ning Zhang, Jing Luo, Debashish Bhattacharya In the past decade, advances in next-generation sequencing technologies and bioinformatic pipelines for phylogenomic analysis have led to remarkable progress in fungal systematics and taxonomy. A number of long-standing questions have been addressed using comparative analysis of genome sequence data, resulting in robust multigene phylogenies. These have added to, and often surpassed traditional morphology or single-gene phylogenetic methods. In this chapter, we provide a brief history of fungal systematics and highlight some examples to demonstrate the impact of phylogenomics on this field. We conclude by discussing some of the challenges and promises in fungal biology posed by the ongoing genomics revolution.
Print ISSN: 0065-2660
Topics: Biology
Published by Elsevier
2.
PAPER CURRENT
Rational Engineering of Bioinspired Anthocyanidin Fluorophores with Excellent Two-Photon Properties for Sensing and Imaging (2017)
American Chemical Society (ACS)
Publication Date: 2017-10-22
Description: Analytical Chemistry DOI: 10.1021/acs.analchem.7b02538
Print ISSN: 0003-2700
Electronic ISSN: 1520-6882
Topics: Chemistry and Pharmacology
3.
PAPER CURRENT
Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles (2017)
Elsevier
Publication Date: 2017-10-22
Description: Publication date: January 2018 Source: Biomaterials, Volume 151 Author(s): Tian Zhou, Hang Su, Prasanta Dash, Zhiyi Lin, Bhagya Laxmi Dyavar Shetty, Ted Kocher, Adam Szlachetka, Benjamin Lamberty, Howard S. Fox, Larisa Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, R. Lee Mosley, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations. Despite this excellent profile, high volume dosing, injection site reactions and low body fluid drug concentrations affect broad use for virus infected and susceptible people. To improve the drug delivery profile, we created a myristoylated CAB prodrug (MCAB). MCAB formed crystals that were formulated into nanoparticles (NMCAB) of stable size and shape facilitating avid monocyte-macrophage entry, retention and reticuloendothelial system depot formulation. Drug release kinetics paralleled sustained protection against HIV-1 challenge. After a single 45 mg/kg intramuscular injection to BALB/cJ mice, the NMCAB pharmacokinetic profiles was 4-times greater than that recorded for CAB LAP. These observations paralleled replicate measurements in rhesus macaques. The results coupled with improved viral restriction in human adult lymphocyte reconstituted NOD/SCID/IL2Rγc −/− mice led us to conclude that NMCAB can improve biodistribution and viral clearance profiles upon current CAB LAP formulations.
Print ISSN: 0142-9612
Electronic ISSN: 1878-5905
Topics: Biology , Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision Mechanics , Medicine
Published by Elsevier
4.
PAPER CURRENT
Cancers, Vol. 9, Pages 139: CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth (2017)
Molecular Diversity Preservation International (MPDI)
Publication Date: 2017-10-22
Description: Cancers, Vol. 9, Pages 139: CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth Cancers doi: 10.3390/cancers9100139 Authors: Vita Golubovskaya Robert Berahovich Hua Zhou Shirley Xu Hizkia Harto Le Li Cheng-Chi Chao Mike Ming Mao Lijun Wu CD47 is a glycoprotein of the immunoglobulin superfamily that is often overexpressed in different types of hematological and solid cancer tumors and plays important role in blocking phagocytosis, increased tumor survival, metastasis and angiogenesis. In the present report, we designed CAR (chimeric antigen receptor)-T cells that bind CD47 antigen. We used ScFv (single chain variable fragment) from mouse CD47 antibody to generate CD47-CAR-T cells for targeting different cancer cell lines. CD47-CAR-T cells effectively killed ovarian, pancreatic and other cancer cells and produced high level of cytokines that correlated with expression of CD47 antigen. In addition, CD47-CAR-T cells significantly blocked BxPC3 pancreatic xenograft tumor growth after intratumoral injection into NSG mice. Moreover, we humanized mouse CD47 ScFv and showed that it effectively bound CD47 antigen. The humanized CD47-CAR-T cells also specifically killed ovarian, pancreatic, and cervical cancer cell lines and produced IL-2 that correlated with expression of CD47. Thus, CD47-CAR-T cells can be used as a novel cellular therapeutic agent for treating different types of cancer.
Electronic ISSN: 2072-6694
Topics: Medicine
5.
PAPER CURRENT
Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation (2017)
Nature Publishing Group (NPG)
Publication Date: 2017-10-22
Description: Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation Cell Death and Differentiation 24, 1853 (November 2017). doi:10.1038/cdd.2017.107 Authors: Kay E Gurley, Amanda K Ashley, Russell D Moser & Christopher J Kemp
Print ISSN: 1350-9047
Electronic ISSN: 1476-5403
Topics: Biology , Medicine
6.
PAPER CURRENT
Culling of APCs by inflammatory cell death pathways restricts TIM3 and PD-1 expression and promotes the survival of primed CD8 T cells (2017)
Nature Publishing Group (NPG)
Publication Date: 2017-10-22
Description: Culling of APCs by inflammatory cell death pathways restricts TIM3 and PD-1 expression and promotes the survival of primed CD8 T cells Cell Death and Differentiation 24, 1900 (November 2017). doi:10.1038/cdd.2017.112 Authors: Rajen Patel, Kwangsin Kim, Bojan Shutinoski, Kristina Wachholz, Lakshmi Krishnan & Subash Sad
Print ISSN: 1350-9047
Electronic ISSN: 1476-5403
Topics: Biology , Medicine
7.
PAPER CURRENT
Publication Date: 2017-10-22
Description: High mobility group A1 protein modulates autophagy in cancer cells Cell Death and Differentiation 24, 1948 (November 2017). doi:10.1038/cdd.2017.117 Authors: Andrea Conte, Simona Paladino, Gaia Bianco, Dominga Fasano, Raffaele Gerlini, Mara Tornincasa, Maurizio Renna, Alfredo Fusco, Donatella Tramontano & Giovanna Maria Pierantoni
Print ISSN: 1350-9047
Electronic ISSN: 1476-5403
Topics: Biology , Medicine
8.
PAPER CURRENT
The emerging role of RNAs in DNA damage repair (2017)
Nature Publishing Group (NPG)
Publication Date: 2017-10-22
Description: The emerging role of RNAs in DNA damage repair Cell Death and Differentiation 24, 1989 (November 2017). doi:10.1038/cdd.2017.146 Authors: Ben R Hawley, Wei-Ting Lu, Ania Wilczynska & Martin Bushell
Print ISSN: 1350-9047
Electronic ISSN: 1476-5403
Topics: Biology , Medicine
9.
PAPER CURRENT
Data on fluoride concentration levels in cold and warm season in rural area of Shout (West Azerbaijan, Iran) (2017)
Elsevier
Publication Date: 2017-10-22
Description: Publication date: December 2017 Source: Data in Brief, Volume 15 Author(s): Farzaneh Baghal Asghari, Ali Akbar Mohammadi, Zahra Aboosaedi, Mehdi Yaseri, Mahmood Yousefi The aim of this study was to determine the concentration of fluoride in drinking water, the distribution system, in 22 villages in Shout (A city in West Azerbaijan province). Sampling of springs and underground water was carried out in two warm and cold seasons. Fluoride concentration were determined through spectrophotometer with a model, DR/5000.The fluoride concentration were compared with Iranian standards and WHO guidelines for drinking water.
Print ISSN: 2352-3409
Topics: Biology
Published by Elsevier
10.
PAPER CURRENT
Publication Date: 2017-10-22
Description: In the phase 3, RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), nonfunctional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.35-0.67; P  < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best supportive care. This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures. Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n  = 63 and placebo, n  = 27). Median PFS (95% CI) by central review was 9.2 (6.8-10.9) months in everolimus arm vs 3.6 (1.9-5.1) months in placebo arm (HR, 0.50; 95% CI, 0.28-0.88). More patients who received everolimus (58%) experienced any tumor shrinkage compared with placebo (13%). Most frequently reported (≥ 5% incidence) grade 3-4 drug-related adverse events (everolimus vs placebo) included stomatitis (11% vs 0%), hyperglycemia (10% vs 0%), and any infections (8% vs 0%). In patients with advanced, progressive, well-differentiated, nonfunctional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 population. These results support the use of everolimus in patients with advanced, nonfunctional lung NET. This article is protected by copyright. All rights reserved.
Topics: Medicine